RxDoctor Payments Data

Thomas Davis, MD

Family Medicine · Oakdale, LANPI 1548320161

Payments from drug & device makers

$1,760in general payments, 2019–2025

Across 127 payments — averaging $13.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$367
  • Novartis$199
  • Sunovion Pharmaceuticals Inc.$176
  • Lilly USA, LLC$175
  • AbbVie$167
  • AstraZeneca$106
  • plus $570 from 14 others

What the payments were for

  • Food & beverage$1,74999%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,760 in reported general payments places this provider in the 65th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$997
Medicare patients
15
Services billed
18

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide176$177,549
JardianceEmpagliflozin209$118,818
EliquisApixaban213$112,160
TrulicityDulaglutide70$98,911
IngrezzaValbenazine Tosylate24$93,548
MounjaroTirzepatide60$74,165
RybelsusSemaglutide50$60,107
LinzessLinaclotide95$56,758
FarxigaDapagliflozin Propanediol80$49,464
EntrestoSacubitril/Valsartan49$42,491
NuplazidPimavanserin Tartrate16$39,769
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$39,436
XareltoRivaroxaban61$34,969
Breo ElliptaFluticasone/Vilanterol54$30,123
Tresiba Flextouch U-200Insulin Degludec37$24,175

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$367$237,656226 claims
Lilly USA, LLCTrulicity, Mounjaro$175$173,076130 claims
Boehringer IngelheimJardiance, Spiriva Respimat$34$129,969223 claims
PfizerEliquis, Premarin$45$119,358233 claims
GSKTrelegy Ellipta, Breo Ellipta$59$69,55986 claims
AbbVieLinzess, Vraylar$167$67,369110 claims
AstraZenecaFarxiga, Brilinta$106$58,562106 claims
NovartisEntresto$199$42,49149 claims
Sanofi-aventis U.S. LLCMultaq$54$14,33926 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$56$6,50611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Oakdale

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →